羟氯喹：危害还是治疗。
Clioquinol: To harm or heal.
机构信息
University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
出版信息
Pharmacol Ther. 2019 Jul;199:155-163. doi: 10.1016/j.pharmthera.2019.03.009. Epub 2019 Mar 18.
Clioquinol, one of the first mass-produced drugs, was considered safe and efficacious for many years. It was used as an antifungal and an antiprotozoal drug until it was linked to an outbreak of subacute myelo-optic neuropathy (SMON), a debilitating disease almost exclusively confined to Japan. Today, new information regarding clioquinol targets and its mechanism of action, as well as genetic variation (SNPs) in efflux transporters in the Japanese population, provide a unique interpretation of the existing phenomena. Further understanding of clioquinol's role in the inhibition of cAMP efflux and promoting apoptosis might offer promise for the treatment of cancer and/or neurodegenerative diseases. Here, we highlight recent developments in the field and discuss possible connections, hypotheses and perspectives in clioquinol-related research.
曲安西龙，最早大规模生产的药物之一，多年来被认为是安全有效的。它被用作抗真菌和抗原生动物药物，直到它与亚急性脊髓视神经病（SMON）的爆发有关，这是一种几乎只局限于日本的使人衰弱的疾病。如今，有关曲安西龙的靶点及其作用机制的新信息，以及日本人群中流出转运蛋白的遗传变异（SNP），为现有现象提供了独特的解释。进一步了解曲安西龙在抑制 cAMP 外流和促进细胞凋亡中的作用，可能为癌症和/或神经退行性疾病的治疗带来希望。在这里，我们强调了该领域的最新进展，并讨论了曲安西龙相关研究中可能的联系、假设和观点。
Zotero 插件